-+ 0.00%
-+ 0.00%
-+ 0.00%

LUCID CAPITAL MARKETS Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $24

Benzinga·09/24/2026 11:41:02
Diffusion vocale
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Turn Therapeutics (NASDAQ:TTRX) with a Buy rating and announces Price Target of $24.